Full Text
MODELING THE BUDGET IMPACT OF AVAILABILITY OF BIOSIMILARS OF INFLIXIMAB AND ADALIMUMAB FOR TREATMENT FOR RHEUMATOID ARTHRITIS USING PUBLISHED CLAIM-BASED ALGORITHM DATA IN THE UNITED STATES

Abstract

Authors

A. Shah M. Mwamburi

Back to Volume 19, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×